Literature DB >> 26982340

OUTCOMES AFTER PARS PLANA VITRECTOMY FOR EPIRETINAL MEMBRANES ASSOCIATED WITH TOXOPLASMOSIS.

Ana F Miranda1, Gabriel Costa de Andrade, Eduardo A Novais, André Maia, Heloisa Nascimento, Cristina Muccioli, Rubens Belfort.   

Abstract

PURPOSE: To evaluate outcomes and complications of pars plana vitrectomy in patients with epiretinal membrane secondary to toxoplasmic retinochoroiditis.
METHODS: Retrospective evaluation of the records of 14 patients who underwent pars plana vitrectomy for epiretinal membrane secondary to toxoplasmic retinochoroiditis. The best-corrected visual acuity, intraoperative and postoperative complications, and macular optical coherence tomography were analysed. All patients received postoperative prophylactic treatment with trimethoprim/sulfamethoxazole.
RESULTS: Fourteen patients, 5 men and 9 women, were included. Mean follow-up period after surgery was 6.07 ± 2.64 months. Preoperative mean best-corrected visual acuity was 20/200, and postoperative mean best-corrected visual acuity was 20/60. There were no intraoperative complications. Three patients developed posterior capsule opacification, and one patient developed cataract.
CONCLUSION: Pars plana vitrectomy is a safe and effective procedure in patients with epiretinal membrane secondary to toxoplasmic retinochoroiditis, improving both visual acuity and anatomical result on macular optical coherence tomography. The most frequent postoperative complications were posterior capsule opacification and cataract. No recurrences of the disease were recorded.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26982340     DOI: 10.1097/IAE.0000000000000973

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  1 in total

1.  Anatomical and functional outcomes of pars plana vitrectomy for inflammatory epiretinal membrane surgery in healed toxoplasmosis infection.

Authors:  Vishal Raval; Srinivas Rao; Taraprasad Das
Journal:  Indian J Ophthalmol       Date:  2018-10       Impact factor: 1.848

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.